NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AlphaNavi Pharma Inc.

AlphaNavi Pharma Inc.

Private
SuitaHealthcare & Life Scienceshttps://alphanavi.com/en/top/

Last Round

Series B

Mar 1, 2023

Total Funding Raised

$12.66M

Company Overview

AlphaNavi Pharma Inc. is a biopharmaceutical company that develops novel analgesic drugs for patients suffering from pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

non-opioid analgesicneuropathic pain treatmentopioid alternativesodium channel inhibitorclinical-stage biotechsmall molecule drugrare disease therapeuticsNav1.7 inhibitortreatment-resistant painorphan drugdrug out-licensingpharma carve-outgenetic pain disorderstargeted therapyfirst-in-class therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AlphaNavi Pharma Inc. Comparables

Compare AlphaNavi Pharma Inc. with similar companies based on industry and business-model similarity.

AlphaNavi Pharma Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eli Lilly and Company
82%
Guangzhou Fermion Technology Co., Ltd.
82%
Latigo Biotherapeutics
76%

AlphaNavi Pharma Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 1, 2023
Series AMar 28, 2019

Key People

Founding team and executive leadership

小山田義博

Co-founder And CEO

Founding Team

Hirotsugu Hayashi

Chief Operating Officer

Executive Team

AlphaNavi Pharma Inc. Investors

Notable investors and investment history

AlphaNavi Pharma Inc. investors
InvestorRounds
Chushin Venture CapitalSeries A, Series B
Shinsei Capital PartnersSeries A, Series B
日本ベンチャーキャピタル株式会社Series A, Series B
Kyoto University Innovation CapitalSeries A, Series B
SMBC Venture CapitalSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2026

    Monthly visitors grew 91% MoM.

  • Jul 6, 2025

    Monthly visitors increased 38% MoM.

AlphaNavi Pharma Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AlphaNavi Pharma Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AlphaNavi Pharma Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuita
Employee Range4
Year Founded2019
Last FundingMar 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.